Seminars in Oncology
Volume 36, Issue 4 , Pages 302-311, August 2009

Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response AssessmentDisclosures

  • Robert S. Benjamin

      Affiliations

    • Department of Sarcoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX
    • These authors contributed equally to this work.
    • ,
  • Maria Debiec-Rychter

      Affiliations

    • Department of Human Genetics, Catholic University Leuven, Leuven, Belgium
    • These authors contributed equally to this work.
    • ,
  • Axel Le Cesne

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • These authors contributed equally to this work.
    • ,
  • Stefan Sleijfer

      Affiliations

    • Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • These authors contributed equally to this work.
    • ,
  • George D. Demetri

      Affiliations

    • Dana-Farber Cancer Institute, Ludwig Center, Boston, MA
    • These authors contributed equally to this work.
    • ,
  • Heikki Joensuu

      Affiliations

    • Helsinki University Central Hospital, Department of Oncology, Helsinki, Finland
    • These authors contributed equally to this work.
    • ,
  • Patrick Schöffski

      Affiliations

    • University Hospitals Leuven, Department of General Medical Oncology and Laboratory of Experimental Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
    • These authors contributed equally to this work.
    • ,
  • Andrés Poveda

      Affiliations

    • Instituto Valenciano de Oncología, Valencia, Spain
    • These authors contributed equally to this work.
    • Corresponding Author InformationAddress correspondence to Andrés Poveda, MD, Instituto Valenciano de Oncología, Prof Baguena 19, Valencia 46009, Spain

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

Disclosures R.S. Benjamin: Novartis (consulting, speaker's bureau)M. Debiec-Rychter: Novartis (research support)A. Le Cesne: Novartis (honoraria)S. Sleijfer: Pfizer, Novartis (research support)G.D. Demetri: Novartis, Pfizer, Ariad, Johnson & Johnson, Genentech, Plexxikon, Bristol Meyers Squibb Research, Infinity Pharmaceuticals, Ziopharm, Alnylam, Idera, Bayer, Serono, Amgen (research support, consulting)H. Joensuu: Novartis, Bayer-Schering Pharma (honoraria), testimony (Pfizer)P. Schöffski: Novartis (research funding and honoraria); Pfizer (research funding and honoraria)A. Poveda: none

PII: S0093-7754(09)00103-1

doi:10.1053/j.seminoncol.2009.06.003

Seminars in Oncology
Volume 36, Issue 4 , Pages 302-311, August 2009

Article Tools

* Image Usage & Resolution